Cargando…
Cisplatin-induced haemolytic uraemic syndrome associated with a novel intronic mutation of CD46 treated with eculizumab
A 2-year-old patient with a neuroblastoma developed haemolytic uraemic syndrome (HUS) following treatment with cisplatin and carboplatin. Following treatment with eculizumab, there was a substantial improvement in renal function with the recovery of the platelet count and the cessation of haemolysis...
Autores principales: | Gilbert, Rodney D., Stanley, Louise K., Fowler, Darren J., Angus, Elizabeth M., Hardy, Steven A., Goodship, Timothy H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888095/ https://www.ncbi.nlm.nih.gov/pubmed/24422172 http://dx.doi.org/10.1093/ckj/sft065 |
Ejemplares similares
-
Eculizumab and drug-induced haemolytic–uraemic syndrome
por: Faguer, Stanislas, et al.
Publicado: (2013) -
Atypical haemolytic uraemic syndrome associated with a CD46 mutation triggered by Shigella flexneri
por: Brocklebank, Vicky, et al.
Publicado: (2014) -
Eculizumab in secondary atypical haemolytic uraemic syndrome
por: Cavero, Teresa, et al.
Publicado: (2017) -
Early treatment with eculizumab in atypical haemolytic uraemic syndrome
por: Garjau, Maria, et al.
Publicado: (2012) -
Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome
por: Walsh, Patrick R., et al.
Publicado: (2018)